tetano
Editor, Senior Moderator
Drugs. 2018 Sep 8. doi: 10.1007/s40265-018-0981-8. [Epub ahead of print]
[h=1]Peramivir: A Review in Uncomplicated Influenza.[/h] Scott LJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Intravenous peramivir (Alpivab?; Rapivab[SUP]?[/SUP]; Rapiacta[SUP]?[/SUP]; PeramiFlu[SUP]?[/SUP]), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of peramivir in this indication and summarizes its pharmacological properties. In large, randomized, double-blind, multicentre trials in previously healthy adults with uncomplicated influenza, a single infusion of peramivir 600 mg significantly shortened the median time to resolution of influenza symptoms compared with placebo and was noninferior to the recommended oseltamivir regimen in terms of this primary outcome. Albeit data are limited, results from a noncomparative phase 3 trial in paediatric patients (≈ 95% of whom were aged ≥ 2 years) with acute uncomplicated influenza receiving the recommended dose of peramivir were generally consistent with those in adults. Peramivir was generally well tolerated in children and adults participating in these clinical trials, with most adverse events of mild to moderate intensity. Given its simple single-dose regimen and with intravenous administration offering a potential advantage over oral administration in individuals with nausea, vomiting or having difficulty in swallowing, peramivir provides an additional option for treating uncomplicated influenza infection in adults and children from the age of 2 years.
PMID: 30196350 DOI: 10.1007/s40265-018-0981-8
[h=1]Peramivir: A Review in Uncomplicated Influenza.[/h] Scott LJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Intravenous peramivir (Alpivab?; Rapivab[SUP]?[/SUP]; Rapiacta[SUP]?[/SUP]; PeramiFlu[SUP]?[/SUP]), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of peramivir in this indication and summarizes its pharmacological properties. In large, randomized, double-blind, multicentre trials in previously healthy adults with uncomplicated influenza, a single infusion of peramivir 600 mg significantly shortened the median time to resolution of influenza symptoms compared with placebo and was noninferior to the recommended oseltamivir regimen in terms of this primary outcome. Albeit data are limited, results from a noncomparative phase 3 trial in paediatric patients (≈ 95% of whom were aged ≥ 2 years) with acute uncomplicated influenza receiving the recommended dose of peramivir were generally consistent with those in adults. Peramivir was generally well tolerated in children and adults participating in these clinical trials, with most adverse events of mild to moderate intensity. Given its simple single-dose regimen and with intravenous administration offering a potential advantage over oral administration in individuals with nausea, vomiting or having difficulty in swallowing, peramivir provides an additional option for treating uncomplicated influenza infection in adults and children from the age of 2 years.
PMID: 30196350 DOI: 10.1007/s40265-018-0981-8